跳至主要内容
临床试验/CTRI/2020/07/026820
CTRI/2020/07/026820尚未招募4 期

Curcumin for COVID-19 Pre Exposure Prophylaxis: A Randomised Controlled Trail

Rohit Walia1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2020年9月8日最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方
Rohit Walia
入组人数
200
试验地点
1
主要终点
1. SARS-CoV 2 infection rate Using RTPCR

研究概览

简要总结

Curcumin has been proven to have anti viral , anti bacterial and anti inflammatory properties and immunomodulator. We plan to a randomised controlled trail to study curcumin as pre exposure prophylaxis in healthcare workers and high risk groups and look for Covid infection rates over a period of 12 weeks and look for COVID positivity rates over a period of 12 weeks between cur cumin vs. placebo.

研究设计

研究类型
Interventional
分配方式
Computer generated randomization
盲法
Participant and Investigator Blinded

入排标准

年龄范围
18.00 Year(s) 至 70.00 Year(s)(—)
性别
All

入选标准

  • People at risk of SARS-CoV 2 infection ( healthcare professionals , attendants of COVID patients , non COVID patients admitted in hospitals or his risk groups like elderly , cardiovascular patients , diabetes , obesity ) Not having a previous COVID19 diagnosis Not having experienced COVID19 symptoms since 30 th Jan
  • Not having taken any pre-exposure prophylaxis ( HCQ , any other medication or Ayurvedic preparation or food supplement ) Having a negative SARS-CoV 2 test before randomisation.

排除标准

  • Any chronic infection Renal failure (CrCl < 60 mL/min/1.73 m2) or need for hemodialysis Known history of hypersensitivity to the study drug or any of its components Immune suppressant drugs Recent vaccination within 2 month Pregnancy Primary Immunodeficiency states • Anemia Leukopenia Thrombocytopenia Co morbidities precluding survival required for duration of study follow up.

结局指标

主要结局

1. SARS-CoV 2 infection rate Using RTPCR

时间窗: 12 weeks

次要结局

  • Frequency of respiratory tract infections during course of study using the Wisconsin Upper Respiratory Symptom Survey
  • Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.(12 weeks)

研究者

发起方
Rohit Walia
申办方类型
Other [Principal investigator ]

研究点 (1)

Loading locations...

相似试验